These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10817 related articles for article (PubMed ID: 1389487)
1. Neuron-specific enolase as a prognostic factor in metastatic malignant melanoma. Wibe E; Hannisdal E; Paus E; Aamdal S Eur J Cancer; 1992; 28A(10):1692-5. PubMed ID: 1389487 [TBL] [Abstract][Full Text] [Related]
2. Neuron-specific enolase as a tumor marker in metastatic melanoma. Buzaid AC; Sandler AB; Hayden CL; Scinto J; Poo WJ; Clark MB; Hotchkiss S Am J Clin Oncol; 1994 Oct; 17(5):430-1. PubMed ID: 8092117 [TBL] [Abstract][Full Text] [Related]
3. Neuron specific enolase (NSE) in serum of patients with malignant melanoma. Wibe E; Paus E; Aamdal S Cancer Lett; 1990 Jun; 52(1):29-31. PubMed ID: 2354416 [TBL] [Abstract][Full Text] [Related]
11. Normal serum neuron specific enolase (NSE) value after the first cycle of chemotherapy: an early predictor of complete response and survival in patients with small cell lung carcinoma. Fizazi K; Cojean I; Pignon JP; Rixe O; Gatineau M; Hadef S; Arriagada R; Baldeyrou P; Comoy E; Le Chevalier T Cancer; 1998 Mar; 82(6):1049-55. PubMed ID: 9506348 [TBL] [Abstract][Full Text] [Related]
12. [Neuron-specific enolase and beta 2-microglobulin in the serum of patients with melanoma]. Uerlich M; Biltz H; Kreysel HW Immun Infekt; 1988 Apr; 16(2):65-7. PubMed ID: 3292403 [TBL] [Abstract][Full Text] [Related]
13. Serum neuron-specific enolase and lactate dehydrogenase as predictors of response to chemotherapy and survival in non-small cell lung cancer. van Zandwijk N; Jassem E; Bonfrer JM; Mooi WJ; van Tinteren H Semin Oncol; 1992 Feb; 19(1 Suppl 2):37-43. PubMed ID: 1329221 [TBL] [Abstract][Full Text] [Related]
14. Neuron-specific enolase--a serum tumour marker in seminoma? Fosså SD; Klepp O; Paus E Br J Cancer; 1992 Feb; 65(2):297-9. PubMed ID: 1739633 [TBL] [Abstract][Full Text] [Related]
15. Neuron-Specific Enolase as a Biomarker: Biochemical and Clinical Aspects. Isgrò MA; Bottoni P; Scatena R Adv Exp Med Biol; 2015; 867():125-43. PubMed ID: 26530364 [TBL] [Abstract][Full Text] [Related]
16. Chromogranin A and neurone-specific enolase variations during the first 3 months of abiraterone therapy predict outcomes in patients with metastatic castration-resistant prostate cancer. Fan L; Wang Y; Chi C; Pan J; Xun S; Xin Z; Hu J; Zhou L; Dong B; Xue W BJU Int; 2017 Aug; 120(2):226-232. PubMed ID: 28107595 [TBL] [Abstract][Full Text] [Related]
17. Serum neuron-specific enolase as a tumor marker in the diagnosis and follow-up of small-cell lung cancer. Pinson P; Joos G; Watripont P; Brusselle G; Pauwels R Respiration; 1997; 64(1):102-7. PubMed ID: 9044484 [TBL] [Abstract][Full Text] [Related]
18. The role of serum neuron-specific enolase in patients with prostate cancer: a systematic review of the recent literature. Muoio B; Pascale M; Roggero E Int J Biol Markers; 2018 Jan; 33(1):10-21. PubMed ID: 28885659 [TBL] [Abstract][Full Text] [Related]
19. Serum neuron-specific enolase is a useful tumor marker for small cell lung cancer. Burghuber OC; Worofka B; Schernthaner G; Vetter N; Neumann M; Dudczak R; Kuzmits R Cancer; 1990 Mar; 65(6):1386-90. PubMed ID: 2155054 [TBL] [Abstract][Full Text] [Related]
20. Pro-gastrin-releasing peptide and neuron-specific enolase: useful predictors of response to chemotherapy and survival in patients with small cell lung cancer. Huang Z; Xu D; Zhang F; Ying Y; Song L Clin Transl Oncol; 2016 Oct; 18(10):1019-25. PubMed ID: 26886220 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]